Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny et al. · New England Journal of Medicine · 2004 · 11K citations · Full text

Medicine, Oncology, Pharmacology +15

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Alan Sandler, Robert J. Gray, Michael C. Perry et al. · New England Journal of Medicine · 2006 · 5.8K citations · Full text

Medicine, Oncology, Pharmacology +13

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak et al. · New England Journal of Medicine · 2007 · 5.8K citations · Full text

Medicine, Oncology, Pharmacology +14

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

Bernard Escudier, Tim Eisen, Walter M. Stadler et al. · New England Journal of Medicine · 2007 · 4.8K citations · Full text

Medicine, Nephrology, Oncology +11

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

Nasser H. Hanna, Frances A. Shepherd, Frank V. Fossella et al. · Journal of Clinical Oncology · 2004 · 2.4K citations · Full text

Medicine, Oncology, Pharmacology +15